Aldosterone blockade in chronic kidney disease

Jamie S. Hirsch, Yelena Drexler, Andrew S. Bomback

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Although blockade of the renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers has become standard therapy for chronic kidney disease (CKD), renewed interest in the role of aldosterone in mediating the injuries and progressive insults of CKD has highlighted the potential role of treatments targeting the mineralocorticoid receptor (MR). Although salt restriction is an important component of mitigating the profibrotic effects of MR activation, a growing body of literature has shown that MR antagonists, spironolactone and eplerenone, can reduce proteinuria and blood pressure in patients at all stages of CKD. These agents carry a risk of hyperkalemia, but this risk likely can be predicted based on baseline renal function and mitigated using dietary modifications and adjustments of concomitant medications. Data on hard outcomes, such as progression to end-stage renal disease and overall mortality, still are lacking in patients with CKD.

Original languageEnglish (US)
Pages (from-to)307-322
Number of pages16
JournalSeminars in Nephrology
Volume34
Issue number3
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Aldosterone
Chronic Renal Insufficiency
Mineralocorticoid Receptors
Mineralocorticoid Receptor Antagonists
Diet Therapy
Spironolactone
Hyperkalemia
Angiotensin Receptor Antagonists
Renin-Angiotensin System
Proteinuria
Angiotensin-Converting Enzyme Inhibitors
Chronic Kidney Failure
Salts
Blood Pressure
Kidney
Mortality
Wounds and Injuries
Therapeutics

Keywords

  • Aldosterone
  • Chronic kidney disease
  • Proteinuria
  • Spironolactone

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)

Cite this

Aldosterone blockade in chronic kidney disease. / Hirsch, Jamie S.; Drexler, Yelena; Bomback, Andrew S.

In: Seminars in Nephrology, Vol. 34, No. 3, 2014, p. 307-322.

Research output: Contribution to journalArticle

Hirsch, JS, Drexler, Y & Bomback, AS 2014, 'Aldosterone blockade in chronic kidney disease', Seminars in Nephrology, vol. 34, no. 3, pp. 307-322. https://doi.org/10.1016/j.semnephrol.2014.04.006
Hirsch, Jamie S. ; Drexler, Yelena ; Bomback, Andrew S. / Aldosterone blockade in chronic kidney disease. In: Seminars in Nephrology. 2014 ; Vol. 34, No. 3. pp. 307-322.
@article{22e30501976a45f39e4178e32fed4a86,
title = "Aldosterone blockade in chronic kidney disease",
abstract = "Although blockade of the renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers has become standard therapy for chronic kidney disease (CKD), renewed interest in the role of aldosterone in mediating the injuries and progressive insults of CKD has highlighted the potential role of treatments targeting the mineralocorticoid receptor (MR). Although salt restriction is an important component of mitigating the profibrotic effects of MR activation, a growing body of literature has shown that MR antagonists, spironolactone and eplerenone, can reduce proteinuria and blood pressure in patients at all stages of CKD. These agents carry a risk of hyperkalemia, but this risk likely can be predicted based on baseline renal function and mitigated using dietary modifications and adjustments of concomitant medications. Data on hard outcomes, such as progression to end-stage renal disease and overall mortality, still are lacking in patients with CKD.",
keywords = "Aldosterone, Chronic kidney disease, Proteinuria, Spironolactone",
author = "Hirsch, {Jamie S.} and Yelena Drexler and Bomback, {Andrew S.}",
year = "2014",
doi = "10.1016/j.semnephrol.2014.04.006",
language = "English (US)",
volume = "34",
pages = "307--322",
journal = "Seminars in Nephrology",
issn = "0270-9295",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Aldosterone blockade in chronic kidney disease

AU - Hirsch, Jamie S.

AU - Drexler, Yelena

AU - Bomback, Andrew S.

PY - 2014

Y1 - 2014

N2 - Although blockade of the renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers has become standard therapy for chronic kidney disease (CKD), renewed interest in the role of aldosterone in mediating the injuries and progressive insults of CKD has highlighted the potential role of treatments targeting the mineralocorticoid receptor (MR). Although salt restriction is an important component of mitigating the profibrotic effects of MR activation, a growing body of literature has shown that MR antagonists, spironolactone and eplerenone, can reduce proteinuria and blood pressure in patients at all stages of CKD. These agents carry a risk of hyperkalemia, but this risk likely can be predicted based on baseline renal function and mitigated using dietary modifications and adjustments of concomitant medications. Data on hard outcomes, such as progression to end-stage renal disease and overall mortality, still are lacking in patients with CKD.

AB - Although blockade of the renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers has become standard therapy for chronic kidney disease (CKD), renewed interest in the role of aldosterone in mediating the injuries and progressive insults of CKD has highlighted the potential role of treatments targeting the mineralocorticoid receptor (MR). Although salt restriction is an important component of mitigating the profibrotic effects of MR activation, a growing body of literature has shown that MR antagonists, spironolactone and eplerenone, can reduce proteinuria and blood pressure in patients at all stages of CKD. These agents carry a risk of hyperkalemia, but this risk likely can be predicted based on baseline renal function and mitigated using dietary modifications and adjustments of concomitant medications. Data on hard outcomes, such as progression to end-stage renal disease and overall mortality, still are lacking in patients with CKD.

KW - Aldosterone

KW - Chronic kidney disease

KW - Proteinuria

KW - Spironolactone

UR - http://www.scopus.com/inward/record.url?scp=84903993734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903993734&partnerID=8YFLogxK

U2 - 10.1016/j.semnephrol.2014.04.006

DO - 10.1016/j.semnephrol.2014.04.006

M3 - Article

VL - 34

SP - 307

EP - 322

JO - Seminars in Nephrology

JF - Seminars in Nephrology

SN - 0270-9295

IS - 3

ER -